The BIOHEART-B (02185) subsidiary developed Iberis multi-pole renal artery radiofrequency ablation system completed the first commercial surgery in Germany.

BIOHEART-B (02185) announced that in February 2025, its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), completed the first commercial surgery in Germany using the Iberis multi-pole renal artery radiofrequency ablation system (Iberis RDN system) developed by the company. The surgery was performed by a team led by Dr. Saarraaken Kulenthiran from the University Hospital of Saarland. There were no reports of complications or adverse events. This case was supported by both Pacific International Group Limited (Pacific) and Antong. As commented by Pacific, "Our transradial (TR) Iberis renal nerve denervation (RDN) catheter provides a less invasive, more ergonomic, and effective treatment option. In this case, a hypertensive patient with an abdominal aortic aneurysm (AAA) who was taking six medications had a high risk of embolism through the femoral artery route, making TR the ideal choice." Antong and Pacific have entered into a strategic partnership for the commercialization of the Iberis RDN system, covering various regions including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of the date of this announcement, the Iberis RDN system is the only renal nerve denervation (RDN) product globally approved for use via both the transradial approach (TRA) and the transfemoral artery approach (TFA). TRA makes RDN safer, more effective, and more cost-effective. The company's ultimate goal is to provide outpatient RDN surgeries for patients worldwide. Antong obtained the CE marking for the Iberis RDN system in Europe in 2016 and is currently conducting a post-market clinical trial, "RADIUS-HTN."